Next 10 |
home / stock / agrx / agrx articles
NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the...
NEW YORK, July 02, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potentia...
Agile Therapeutics will combine with Insud Pharma's US Subsidiary, Exeltis, expanding an already significant Women's Health/contraceptiv...
Agile Therapeutics Inc (OTC:AGRX) shares are trading lower by 61% to $0.24 during Tuesday’s session after the company announced the suspensio...
New York, United States, March 12, 2024 (GLOBE NEWSWIRE) -- Contraception encompasses the use of drugs to prevent pregnancy, the transmission of...
Shares of Etsy, Inc. (NASDAQ: ETSY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial result...
Agile Therapeutics Inc (NASDAQ:AGRX) shares jumped during the trading session on Thursday on a solid volume session volume of 9.91 million, co...
Shares of NVIDIA Corporation (NASDAQ: NVDA) rose sharply in today’s pre-market trading after the company reported better-than-expected fourt...
What is a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future g...
News, Short Squeeze, Breakout and More Instantly...
Agile Therapeutics Inc. Company Name:
AGRX Stock Symbol:
NASDAQ Market:
Agile Therapeutics Inc. Website:
First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pink: AGRX), a women's healthcare com...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in First Quarter 2024 Twirla Demand Expected to Rebound in First Quarter 2...